Neuren announces new appointments to the board of directors

Melbourne, Australia, 4 July 2018: Neuren Pharmaceuticals (ASX: NEU) today announced the appointment of Dianne Angus, Patrick Davies and Jenny Harry as non-executive directors. The new directors bring skills, diversity and experience in drug development and commercialisation that are highly relevant to Neuren as a leading developer of new treatments for neurological disorders. Following these appointments, the composition of the Neuren board will be 4 independent non-executive directors and 2 executive directors.

Dianne Angus is currently interim CEO of the Victorian Australian Medical Association (AMA) and was formerly Chief Operating Officer of the neurological drug development company Prana Biotechnology. Dianne is also a registered Patent and Trademark Attorney.

Patrick Davies has held executive management roles in the healthcare industry for over twenty years, including leading Symbion then EBOS Group as CEO for the last ten years through a period of growth in enterprise value from approximately $450 million to in excess of $3.1 billion.

Dr Jenny Harry is currently CEO of drug development company Ondek and was formerly CEO and Managing Director of Tyrian Diagnostics, leading its transformation and the commercialisation of its first diagnostic product.

Neuren Executive Chairman Richard Treagus commented: “Seeking to capitalise on our current strong position and ensure that the board has the appropriate skills and composition for the future, we have taken the opportunity to appoint three very talented and highly regarded leaders. We are confident that the new directors will make an extremely valuable contribution as Neuren continues to execute on its partnering and drug development activities.”

About Neuren and trofinetide

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Neuren has completed Phase 2 development of trofinetide for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. The programs for trofinetide in Rett syndrome and Fragile X syndrome have each been granted Fast Track designation by the US Food and Drug Administration and Orphan Drug designation in both the United States and the European Union. Trofinetide is a synthetic analogue of a naturally occurring neurotrophic peptide derived from IGF-1, a growth factor produced by brain cells. In animal models, trofinetide exhibits a wide range of important effects including inhibiting neuroinflammation, normalizing the role of microglia, correcting deficits in synaptic function and regulating oxidative stress response.
Contact:
Dr Richard Treagus, Executive Chairman: rtreagus@neurenpharma.com; +61 417 520 509

Forward-looking Statements
This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.